Paid Clinical Trials in Oak Brook, IL
As of August 2026, 41 paid clinical trials are recruiting in Oak Brook, Illinois. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Oak Brook offers studies at sites including Northwestern Medicine Oak Brook for conditions such as Anatomic Stage II Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Recurrent Lung Non-Small Cell Carcinoma. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Oak Brook
Trials by drug in Oak Brook
Filter results
41 clinical trials
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
MOTION Clinical Trial
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
E-Mindfulness Approaches for Living After Breast Cancer
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Medrol Dosepak for Outpatient Total Knee Arthroplasty
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Top Research Study Locations in Oak Brook
Researchers run research studies in Oak Brook, IL at 10 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Northwestern Medicine Oak Brook | Anatomic Stage II Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 33 |
| AMR Chicago | Acne | 1 |
| Alliance For Multispecialty Research - Oak Brook | Atherosclerotic Cardiovascular Disease, Obesity, Overweight | 1 |
| Clinical Trial Site | High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension | 1 |
| Genesis Orthopedics & Sports Medicine | Osteoarthritis, Knee | 1 |
| Northwestern University Oak Brook IL453 | Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | 1 |
| Oak Brook Surg Ctr | Lumbar Spinal Stenosis | 1 |
| Rush Oak Brook Outpatient Center | Total Knee Arthroplasty | 1 |
| Rush Oak Brook Surgery Center | Lumbar Spinal Stenosis | 1 |
| Vanda Investigative Site | Hypertension, Uncontrolled Hypertension | 1 |
Active & Upcoming Studies in Oak Brook (2026)
Recruiting trials in Oak Brook grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (32 active studies)
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial · Phase 3 · National Cancer Institute (NCI)
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · National Cancer Institute (NCI)
Cardiovascular (2 active studies)
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease · Phase 3 · Alnylam Pharmaceuticals
- Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension · Phase 2 · Vanda Pharmaceuticals
Mental health & behavior (1 active study)
- E-Mindfulness Approaches for Living After Breast Cancer · Phase 3 · NRG Oncology
Diabetes & metabolic (1 active study)
Common conditions studied in Oak Brook
- Anatomic Stage II Breast Cancer AJCC v8 (5 active studies)
- Stage IV Lung Cancer AJCC v8 (4 active studies)
- Anatomic Stage IIIA Breast Cancer AJCC v8 (3 active studies)
- Recurrent Lung Non-Small Cell Carcinoma (3 active studies)
- Anatomic Stage I Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage IIIB Breast Cancer AJCC v8 (2 active studies)
Leading research sponsors in Oak Brook
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- NRG Oncology
- Alliance for Clinical Trials in Oncology
- ECOG-ACRIN Cancer Research Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Oak Brook?
There are approximately 41 recruiting clinical trials in Oak Brook, Illinois listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Oak Brook pay participants?
Most recruiting trials in Oak Brook compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Oak Brook?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Oak Brook?
The most common conditions under active study in Oak Brook include Anatomic Stage II Breast Cancer AJCC v8 (5), Stage IV Lung Cancer AJCC v8 (4), Anatomic Stage IIIA Breast Cancer AJCC v8 (3), Recurrent Lung Non-Small Cell Carcinoma (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Oak Brook?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Oak Brook on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Oak Brook?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Oak Brook?
Recruiting research sites in Oak Brook include Northwestern Medicine Oak Brook, AMR Chicago, Alliance For Multispecialty Research - Oak Brook, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Oak Brook right now?
The largest active categories in Oak Brook are Cancer & tumors (32), Cardiovascular (2), Mental health & behavior (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.